Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.
CAS Registry Number
152-62-5
Molecular formula
C21H28O2
Molecular weight
312.4 g/mol
Drug class
Synthetic retroprogesteroneselective progestogen
Mechanism of action
Activates progesterone receptors and produces progestational effects on the endometrium and reproductive axis, supporting secretory endometrial transformation without significant androgenic or glucocorticoid activity.
Indications / reported uses
Treatment of progesterone deficiency-related menstrual disorders and secondary amenorrhoea in countries where dydrogesterone is authorised
Used with oestrogen in hormone replacement therapy to protect the endometrium in women with an intact uterus; specific indications vary by jurisdiction
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
ERA assessment scope
Project-specific environmental risk assessment support
The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.
Phase I exposure screening and trigger evaluation.
Environmental fate and ecotoxicity review, with Phase II work where required.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope
Environmental Risk Assessment (ERA)
ReguSight provides project-specific support for the Dydrogesterone Environmental Risk Assessment (ERA) (the Dydrogesterone ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.
Assessment may cover
Product, active-substance identity, formulation, route and intended-market review.
Phase I environmental exposure screening and applicable trigger evaluation.
Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
Data-gap analysis, study strategy, assumptions and scientific reporting.
The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.